Clinical · Molecular biology · Bioinfo & AI
Identification and functional validation of lipid droplet-associated prognostic biomarkers in breast cancer via integrative multi-omics and machine learning approaches
Summary
This study identified and functionally validated lipid droplet (LD)-associated prognostic biomarkers in breast cancer through integrative multi-omics and machine learning. A prognostic model, built using the StepCox[both]+plsRcox algorithm, effectively stratified patients across molecular subtypes, outperforming traditional ER/PR/HER2 status. Key genes, SQLE and SOCS3, were identified with opposing roles: SQLE promoting adipogenesis and SOCS3 inhibiting it, influencing the tumor microenvironment and immune infiltration. Modulating these genes suppressed tumor growth and polarized macrophages towards an M1 phenotype, highlighting their potential as therapeutic targets.
Critical appraisal
Clinical. This research proposes a robust prognostic model for breast cancer, capable of stratifying patients independently of established clinical markers like ER/PR/HER2 status. The model’s ability to identify high-risk patients with reduced immune infiltration and T-cell dysfunction could guide more personalized treatment strategies, particularly in identifying patients who might benefit from immunotherapies or lipid metabolism-targeting therapies. While promising and validated in large cohorts (TCGA, GEO), prospective Phase II/III trials are needed to confirm direct clinical impact and justify changes in practice. The time to clinical impact could be 3-5 years for integration into clinical trials.
Molecular biology. The study discovered SQLE and SOCS3 as functionally significant, lipid droplet-associated prognostic biomarkers involved in breast cancer metabolic reprogramming and immune modulation. SQLE, enriched in tumor-associated adipocytes, promotes adipogenesis, while SOCS3, enriched in immune cells, inhibits it. This discovery was supported by multi-omics integration (bulk transcriptomic, single-cell RNA-seq, spatial transcriptomic) and validated through in vitro (3T3-L1 adipogenesis, co-culture) and in vivo (orthotopic tumor models) experiments, as well as clinical adipose tissue validation. Modulating these genes showed a direct impact on tumor growth and macrophage polarization, paving the way for targeted therapies focusing on lipid metabolism and immunity.
Bioinfo & AI. The study employed an advanced bioinformatics approach integrating multi-omics data (bulk transcriptomic, single-cell RNA sequencing, spatial transcriptomic) to construct a prognostic model. The StepCox[both]+plsRcox algorithm was specifically chosen for its ability to handle complex data and identify robust biomarkers. The model was validated on independent cohorts (TCGA-BRCA and merged GEO datasets), demonstrating its generalizability. This approach represents an incremental application of machine learning for biomarker identification, with a focus on integrating diverse data types for a more comprehensive understanding. If deployed clinically, such a model could be integrated into clinical decision pipelines for risk stratification and treatment selection, potentially prioritizing patients for targeted therapies or clinical trials.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology